meningiomas
Showing 1 - 25 of 104
Role of the Tumor Microenvironment in Aggressive Meningiomas
Not yet recruiting
- Meningioma
- Surgical waste and Data collect
- (no location specified)
Apr 7, 2023
Seizures, Meningioma Trial in Beijing (Tranexamic acid, 0.9% saline)
Active, not recruiting
- Seizures
- Meningioma
- Tranexamic acid
- 0.9% saline
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Jan 1, 2023
Meningioma Trial in Heidelberg (Carbon Ion Radiotherapy)
Active, not recruiting
- Meningioma
- Carbon Ion Radiotherapy
-
Heidelberg, GermanyUniversity Hopsital Heidelberg
Aug 23, 2022
Meningioma Trial (Radiotherapy 68 Gy(RBE), Radiotherapy 72 Gy(RBE), Radiotherapy 60 Gy(RBE))
Not yet recruiting
- Meningioma
- Radiotherapy 68 Gy(RBE)
- +2 more
- (no location specified)
Aug 2, 2022
Liquid Biopsy in High-grade Gliomas and Meningiomas
Recruiting
- High Grade Glioma
- High Grade Meningioma
-
Milano, MI, Italy
- +4 more
Nov 29, 2022
Meningioma, Meningioma Atypical, Anaplastic Meningioma Trial in Rome (Biological biomarker assessment)
Recruiting
- Meningioma
- +2 more
- Biological biomarker assessment
-
Rome, ItalyFondazione Policlinico Universitario A. Gemelli IRCCS
Mar 29, 2023
Meningioma Trial in Houston (Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography)
Recruiting
- Meningioma
- Computed Tomography
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2022
New Prognostic and Predictive Markers inCohort of Atypical
Recruiting
- Meningioma Atypical
-
Vandoeuvre Les Nancy, Lorraine, FranceGuillaume GAUCHOTTE
Feb 18, 2022
Meningioma Atypical Trial in Milano (Radiosurgery)
Recruiting
- Meningioma Atypical
- Radiosurgery
-
Milano, ItalyUOC Radioterapia
Oct 5, 2021
Semi-automated Segmentation Methods of SSTR PET for Dosimetry
Not yet recruiting
- Refractory Meningioma
- To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
- (no location specified)
Sep 8, 2022
Tranexamic Acid, Intraoperative Blood Loss, Meningioma Trial in Beijing (Continous infusion, Single infusion, Placebo)
Recruiting
- Tranexamic Acid
- +2 more
- Continous infusion
- +2 more
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital, Capital Medical University
Aug 24, 2022
Meningiomas: Optimizing Sequences With Low Doses of Gadolinium
Recruiting
- Meningioma
- sequences T1 FE
-
Bordeaux, France
- +9 more
Mar 18, 2022
Skull Base Meningioma Trial in Heidelberg (Carbon Ion Radiotherapy, Proton Therapy, Hypofractionated Photon Radiotherapy)
Withdrawn
- Skull Base Meningioma
- Carbon Ion Radiotherapy
- +3 more
-
Heidelberg, GermanyUniversity Hospital of Heidelberg, Radiation Oncology
Sep 28, 2021
High Grade Glioma, Meningioma, Embryonal Tumor Trial in United States (LUTATHERA® (Lutetium Lu 177 dotatate))
Recruiting
- High Grade Glioma
- +12 more
- LUTATHERA® (Lutetium Lu 177 dotatate)
-
Aurora, Colorado
- +8 more
Jan 16, 2023
Meningioma Trial in Basel (177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and
Recruiting
- Meningioma
- 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
- +2 more
-
Basel, Basel-Stadt, SwitzerlandUniversity Hospital Basel, Department of Neurosurgery
Aug 2, 2021
Inflammatory Microenvironment in Atypical Meningiomas
Unknown status
- Atypical Meningioma
-
Vandoeuvre Les Nancy, FranceGuillaume GAUCHOTTE
Feb 16, 2021
Multisession Radiosurgery in Large Meningiomas
Unknown status
- Intracranial Meningioma
- Radiotherapy
-
Milan, ItalyFondazione IRCCS Istituto Neurologico C. Besta, Unit of Radiothe
Feb 18, 2021
Optic Nerve Sheath Tumors, Benign Trial in Milano (Multisession Radiosurgery)
Active, not recruiting
- Optic Nerve Sheath Tumors, Benign
- Multisession Radiosurgery
-
Milano, Mi, ItalyInstittuto Nazionale Neurologico Carlo Besta
Feb 18, 2021
Meningioma Trial in Austria, Germany, United States (Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI))
Active, not recruiting
- Meningioma
- Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
-
Phoenix, Arizona
- +16 more
Dec 27, 2022
Meningiomas Trial in Boston (Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg)
Recruiting
- Meningiomas
- Nivolumab - 240 mg
- +4 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 3, 2022
Meningioma, Brain Tumor Trial in Boston, Houston (Intensity Modulated Proton Therapy (IMPT))
Recruiting
- Meningioma
- Brain Tumor
- Intensity Modulated Proton Therapy (IMPT)
-
Boston, Massachusetts
- +1 more
Aug 17, 2020
Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas Trial in New York (RAD001)
Completed
- Neurofibromatosis Type 2
- +2 more
-
New York, New YorkNew York University School of Medicine
May 12, 2020
Meningioma Trial in Marseille (drug, biological, device)
Recruiting
- Meningioma
- Trametinib
- +3 more
-
Marseille, FranceAssistance Publique Hôpitaux de Marseille
Apr 29, 2020